Tocilizumab in COVID-19 therapy: who benefits, and how?

Avidan U. Neumann; Mehmet Goekkaya; Karim Dorgham; Claudia Traidl-Hoffmann; Guy Gorochov

doi:10.1016/S0140-6736(21)01427-6

Tocilizumab in COVID-19 therapy: who benefits, and how?

Avidan U. Neumann
, Mehmet Goekkaya
, Karim Dorgham
, Claudia Traidl-Hoffmann
, Guy Gorochov

Department of Dermatology and Allergology

Universitätsklinikum Augsburg
Technical University and Helmholtz Center Munich
Technical University of Munich
Centre de Recherche Institut du Cerveau et de la Moelle
AP-HP

Research output: Contribution to journal › Letter › peer-review

6 Scopus citations

Original language	English
Pages (from-to)	299-300
Number of pages	2
Journal	The Lancet
Volume	398
Issue number	10297
DOIs	https://doi.org/10.1016/S0140-6736(21)01427-6
State	Published - 24 Jul 2021

Access to Document

10.1016/S0140-6736(21)01427-6

Cite this

@article{0ec4991d05e74b008fe4793bfb0cdb54,

title = "Tocilizumab in COVID-19 therapy: who benefits, and how?",

author = "Neumann, \{Avidan U.\} and Mehmet Goekkaya and Karim Dorgham and Claudia Traidl-Hoffmann and Guy Gorochov",

year = "2021",

month = jul,

day = "24",

doi = "10.1016/S0140-6736(21)01427-6",

language = "English",

volume = "398",

pages = "299--300",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier B.V.",

number = "10297",

}

TY - JOUR

T1 - Tocilizumab in COVID-19 therapy

T2 - who benefits, and how?

AU - Neumann, Avidan U.

AU - Goekkaya, Mehmet

AU - Dorgham, Karim

AU - Traidl-Hoffmann, Claudia

AU - Gorochov, Guy

PY - 2021/7/24

Y1 - 2021/7/24

UR - https://www.scopus.com/pages/publications/85110611765

U2 - 10.1016/S0140-6736(21)01427-6

DO - 10.1016/S0140-6736(21)01427-6

M3 - Letter

C2 - 34303430

AN - SCOPUS:85110611765

SN - 0140-6736

VL - 398

SP - 299

EP - 300

JO - The Lancet

JF - The Lancet

IS - 10297

ER -

Tocilizumab in COVID-19 therapy: who benefits, and how?

Access to Document

Other files and links

Cite this